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Background
Dymista (MP29-02*) is a novel intranasal formulation of
azelastine hydrochloride (AZE) and fluticasone propio-
nate (FP) in an advanced delivery system with a well-
documented effect on allergic rhinitis. Its somewhat bitter
taste is probably derived from AZE, a potent histamine-
H1-receptor antagonist. The taste is sometimes looked
upon as a disadvantage. However, it might be that AZE
induces some of its beneficial effect through activation of
bitter taste receptors. Recent evidence indicates that bitter
taste receptors are present in human upper airway
mucosa in regions associated with high airflow and parti-
culate deposition. Consequently the MP29-02* effects
might be due not only to its anti-histaminic, mast-cell
stabilizing, anti-leukotriene, and anti-inflammatory prop-
erties but also as due to activation of bitter taste
receptors.
Aim
To explore if MP29-02* has the ability to activate bitter
taste receptors using an in-vitro model of isolated murine
airways and to probe the potential bitter taste effects of
MP29-02* on human nasal epithelial cells.
Methods
Bitter taste receptor activation was investigated in isolated
murine airways incubated in tissue baths. Balb/c mice
(male) were used since they are known to have a weak his-
tamine receptor system. MP29-02*, AZE and FP were
added cumulatively to tracheal segments pre-contracted
with Carbachol. Primary human nasal epithelial cell were
cultured in the presence of different concentrations of
MP29-02*, AZE and Chloroquine (a bitter taste TAS2R
agonist) and evaluated in relation to traditional activation
markers, such as VCAM-1 and CD86.
Results and comments
MP29-02* is a potent dilator of pre-contracted airways, an
effect probably mediated by its AZE component. The
obtained results make it clear that this is not the result of
histamine receptor activation. The relaxant response of
MP29-02* and AZE mimics the response induced by the
bitter taste TAS2R agonist, Chloroquine. The mechanisms
behind bitter taste receptor mediated relaxations are not
yet known. The presented experiments rule out the invol-
vement of prostaglandins, cAMP and cGMP (all known to
be common pathways for airway dilation) for both MP29-
02* and Chloroquine. Furthermore, preliminary data indi-
cate that Dymista® has the ability to trigger nasal epithelia
cells in a way that resembles of the effects induced by Aze-
lastin and Chloroquine. There are no known antagonists
for bitter taste receptor, but taken together, the presented
data supports our notion that MP29-02* is a potent bitter
taste agonist, which may contribute to its superior efficacy
over AZE and FP observed in clinical trials.
* Dymista
Authors’ details
1Karolinska Institutet, Division of ENT Diseases, Department of Clinical,
Stockholm, Sweden. 2Karolinska Institutet and Karolinska University Hospital,
Division of ENT Diseases, Stockholm, Sweden.
Published: 26 June 2015
doi:10.1186/2045-7022-5-S4-P17
Cite this article as: Ekstedt et al.: The effect of MP29-02* is mediated via
bitter taste receptors (TAS2R). Clinical and Translational Allergy 2015
5(Suppl 4):P17.
1Karolinska Institutet, Division of ENT Diseases, Department of Clinical,
Stockholm, Sweden
Full list of author information is available at the end of the article
Ekstedt et al. Clinical and Translational Allergy 2015, 5(Suppl 4):P17
http://www.ctajournal.com/content/5/S4/P17
© 2015 Ekstedt et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://
creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
